stoxline Quote Chart Rank Option Currency Glossary
  
SELLAS Life Sciences Group, Inc. (SLS)
14.86  -3.09 (-17.21%)    11-19 16:00
Open: 15.385
High: 16.5399
Volume: 36,199,583
  
Pre. Close: 17.95
Low: 14.23
Market Cap: 3,029(M)
Technical analysis
2026-11-20 7:50:13 AM
Short term     
Mid term     
Targets 6-month :  21.15 1-year :  29.07
Resists First :  18.1 Second :  24.88
Pivot price 10.21
Supports First :  7.13 Second :  5.94
MAs MA(5) :  13.45 MA(20) :  10.44
MA(100) :  11.94 MA(250) :  7.81
MACD MACD :  0.7 Signal :  -0.2
%K %D K(14,3) :  57.3 D(3) :  43.8
RSI RSI(14): 60.1
52-week High :  24.88 Low :  1.38
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SLS ] has closed below upper band by 18.4%. Bollinger Bands are 231.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.57 - 16.67 16.67 - 16.77
Low: 14 - 14.09 14.09 - 14.19
Close: 14.68 - 14.85 14.85 - 15.03
Company Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Headline News

Fri, 20 Nov 2026
SELLAS Life Sciences Prices $150 Million Stock Offering at $13 Per Share - TradingView

Fri, 20 Nov 2026
Sellas Life Sciences Scores A Big Win: Here's What We Know (And What We Don't) (Rating Upgrade) - Seeking Alpha

Wed, 18 Nov 2026
SLS Stock Plunges Overnight: Sellas Stock Offering At Nearly 30% Discount Tests Retail Bulls After AML Trial Win - Stocktwits

Wed, 18 Nov 2026
SELLAS Life Sciences Group, Inc. (SLS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Wed, 18 Nov 2026
SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering - GlobeNewswire

Tue, 17 Nov 2026
Sellas Life Sciences: REGAL Hits, But The Data Leaves Too Many Questions Unanswered (SLS) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 202 (M)
Shares Float 201 (M)
Held by Insiders 0.9 (%)
Held by Institutions 37.2 (%)
Shares Short 53,760 (K)
Shares Short P.Month 59,070 (K)
Stock Financials
EPS -0.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.68
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -23.3 %
Return on Equity (ttm) -39.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -28 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -70.77
PEG Ratio 0
Price to Book value 21.85
Price to Sales 0
Price to Cash Flow -105.6
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android